Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
November 11, 2023 at 12:40 PM EST
Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million upfront and up to $1.8 billion in milestones.
